STOCK TITAN

TWST insider filing: 140-share Rule 144 notice, prior sales disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Twist Bioscience insider filings show a proposed sale under Rule 144 and multiple recent disposals of common stock. The notice reports an intended sale of 140 shares through Fidelity Brokerage Services with an approximate sale date of 10/02/2025 and an aggregate market value of $4,082.53. The shares were acquired on 10/01/2025 by restricted stock vesting and were paid as compensation. The filer also disclosed five prior sales by Paula Green between 07/02/2025 and 09/22/2025, totaling 3,203 shares and gross proceeds of $86,716.21. The filing records 60,360,925 shares outstanding for the issuer and includes the required attestation that no undisclosed material adverse information is known to the seller.

Positive

  • Form 144 filed, indicating compliance with Rule 144 disclosure requirements
  • Filing includes seller's attestation of no undisclosed material adverse information

Negative

  • Insider disclosed a proposed sale of 140 shares scheduled for 10/02/2025
  • Five prior insider sales totaling 3,203 shares occurred between 07/02/2025 and 09/22/2025

Insights

Insider plans a small Rule 144 sale; recent sales show ongoing dispositions.

The filing shows a proposed sale of 140 shares on 10/02/2025 following a restricted stock vesting on 10/01/2025, with payment characterized as compensation. The notice also lists five prior sales by Paula Green from 07/02/2025 to 09/22/2025 totaling 3,203 shares and $86,716.21 gross proceeds.

This is a standard Rule 144 disclosure documenting insider liquidity events and compliance with resale rules. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.

Monitor the approximate sale date of 10/02/2025 for execution details if tracking insider activity.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for Twist Bioscience (TWST) report?

The form reports a proposed sale of 140 common shares under Rule 144, an approximate sale date of 10/02/2025, and prior insider sales totaling 3,203 shares.

Who is the selling party disclosed in the filing?

The recent sales are listed for Paula Green, and the current notice indicates the securities were acquired by the filer from the issuer via restricted stock vesting.

How were the 140 shares acquired and paid for?

The shares were acquired on 10/01/2025 through restricted stock vesting and the payment is recorded as compensation on 10/01/2025.

What aggregate proceeds did the prior insider sales generate?

The five prior sales by Paula Green generated gross proceeds of $86,716.21.

How many shares outstanding does the filing report for the issuer?

The filing reports 60,360,925 shares outstanding.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.77B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO